Digestive and Liver Disease
Volume 42, Issue 7 , Pages 468-469 , July 2010

Amantadine for treatment of hepatitis C: Time to say “enough is enough”?

  • Paola Piccolo

      Affiliations

    • Hepatology Unit, Tor Vergata University, Rome, Italy
    • Internal Medicine, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy
    • Corresponding Author InformationCorrespondence address: Hepatology Unit, Tor Vergata University, Via Montpellier 00135, Rome, Italy. Tel.: +39 0672596803.

References 

  1. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci. 1997;42:1681–1687
  2. Mangia A, Leandro G, Helbling B, et al. Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol. 2004;40:478–483
  3. Younossi ZM, Mullen KD, Zakko W, et al. A randomized, double-blind controlled trial of interferon α-2b and ribavirin vs. interferon α-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. J Hepatol. 2001;34:128–133
  4. Deltenre P, Henrion J, Canva V, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol. 2004;41:462–473
  5. Angelico M, Koehler-Horst B, Piccolo P, et al. Peginterferon α-2a and ribavirin versus peginterferon α-2a monotherapy in early virological responders and peginterferon α-2a and ribavirin versus peginterferon α-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2008;20:680–687
  6. Ciancio A, Picciotto A, Giordanino C, et al. A randomized trial of pegylated-interferon-α-2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Aliment Pharmacol Ther. 2006;24:1079–1086
  7. Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon α-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44:275–282
  8. von Wagner M, Hofmann WP, Teuber G, et al. Placebo-controlled trial of 400mg amantadine combined with peginterferon α-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology. 2008;48:1404–1411
  9. van Soest H, van der Schaar PJ, Koek GH, et al. No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis. 2010;42:496–502

PII: S1590-8658(10)00140-4

doi: 10.1016/j.dld.2010.04.009

Digestive and Liver Disease
Volume 42, Issue 7 , Pages 468-469 , July 2010

Article Tools